Durvalumab (MEDI4736) in Frail and Elder Patients With Metastatic NSCLC (DURATION)

Conditions:   Carcinoma, Non-Small-Cell Lung;   Metastatic Lung Cancer;   Non Small Cell Lung Cancer;   Lung Adenocarcinoma Metastatic;   Large Cell Lung Carcinoma Metastatic Interventions:   Drug: Durvalumab;   Drug: Vinorelbine;   Drug: Gemcitabine;   Drug: nab-Paclitaxel;   Drug: Carboplatin Sponsors:   AIO-Studien-gGmbH;   AstraZeneca;   Celgene Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials